Kayfix-OL Tablet is a combination antibiotic formulation containing Cefixime 200 mg, Ofloxacin 200 mg, and Lactobacillus 2.5 million spores, designed for the treatment of a broad spectrum of bacterial infections. Cefixime, a third-generation cephalosporin, exhibits bactericidal activity by inhibiting bacterial cell wall synthesis, effective against various gram-positive and gram-negative pathogens. Ofloxacin, a fluoroquinolone antibiotic, acts by inhibiting bacterial DNA gyrase and topoisomerase IV, thereby preventing DNA replication and transcription, enhancing the antimicrobial spectrum against resistant strains. The inclusion of Lactobacillus spores aids in maintaining and restoring normal gut flora, reducing the risk of antibiotic-associated diarrhea and promoting gastrointestinal health during and after antibiotic therapy. Kayfix-OL is indicated for respiratory tract infections, urinary tract infections, gastrointestinal infections, and skin and soft tissue infections caused by susceptible organisms. It should be used under medical supervision, with dosage and duration tailored to the severity and type of infection. Caution is advised in patients with known hypersensitivity to cephalosporins, fluoroquinolones, or probiotics. Adverse effects may include gastrointestinal disturbances, hypersensitivity reactions, and, rarely, tendonitis or central nervous system effects. Kayfix-OL Tablet offers a synergistic approach to managing complex infections while supporting gut microbiota integrity.